Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy

Journal of the American College of Cardiology

Volumn 68, Issue 25, 2016, Pages 2871-2886

  Burke, Michael A ^a,b   Cook, Stuart A ^c,d,e   Seidman, Jonathan G ^b   Seidman, Christine E ^b,f,g  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d DEPARTMENT OF CARDIOLOGY   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

dilated cardiomyopathy; genetic testing; genetics; hypertrophic cardiomyopathy; molecular etiology; restrictive cardiomyopathy

Indexed keywords

CARDIOMYOPATHY; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; DRUG TARGETING; GENE MUTATION; GENE ONTOLOGY; GENETIC ASSOCIATION; GENETIC SCREENING; GENOMICS; HEART DISEASE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTRICTIVE CARDIOMYOPATHY; REVIEW; CARDIOMYOPATHIES; GENETICS; PHENOTYPE; PROCEDURES;

CARDIOMYOPATHIES; GENETIC TESTING; GENOMICS; HUMANS; PHENOTYPE;

EID: 85006355725     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.08.079     Document Type: Review

References (144)

1. 1 Maron, B.J., Towbin, J.A., Thiene, G., et al. Contemporary definitions and classification of the cardiomyopathies. Circulation 113 (2006), 1807–1816.
2. 2 Elliott, P., Andersson, B., Arbustini, E., et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29 (2008), 270–276.
3. 3 Jarcho, J.A., McKenna, W., Pare, J.A., et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 321 (1989), 1372–1378.
4. 4 Richards, S., Aziz, N., Bale, S., et al., ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17 (2015), 405–424.
5. 5 Lek, M., Karczewski, K., Minikel, E., et al., Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536 (2016), 285–291.
6. 6 Walsh, R., Thomson, K.L., Ware, J.S., et al., Exome Aggregation Consortium. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med, 2016 Aug 17 [E-pub ahead of print].
7. 7 Norton, N., Robertson, P.D., Rieder, M.J., et al., National Heart, Lung and Blood Institute GO Exome Sequencing Project. Evaluating pathogenicity of rare variants from dilated cardiomyopathy in the exome era. Circ Cardiovasc Genet 5 (2012), 167–174.
8. 8 Pan, S., Caleshu, C.A., Dunn, K.E., et al. Cardiac structural and sarcomere genes associated with cardiomyopathy exhibit marked intolerance of genetic variation. Circ Cardiovasc Genet 5 (2012), 602–610.
9. 9 Watkins, H., Thierfelder, L., Anan, R., et al. Independent origin of identical beta cardiac myosin heavy-chain mutations in hypertrophic cardiomyopathy. Am J Hum Genet 53 (1993), 1180–1185.
10. 10 Gersh, B.J., Maron, B.J., Bonow, R.O., et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58 (2011), e212–e260.
11. 11 Wigle, E.D., Rakowski, H., Kimball, B.P., et al. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 92 (1995), 1680–1692.
12. 12 Nagueh, S.F., Mahmarian, J.J., Noninvasive cardiac imaging in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 48 (2006), 2410–2422.
13. 13 Maron, B.J., Gardin, J.M., Flack, J.M., et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 92 (1995), 785–789.
14. 14 Zou, Y., Song, L., Wang, Z., et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med 116 (2004), 14–18.
15. 15 Morita, H., Larson, M.G., Barr, S.C., et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation 113 (2006), 2697–2705.
16. 16 Bick, A.G., Flannick, J., Ito, K., et al. Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. Am J Hum Genet 91 (2012), 513–519.
17. 17 Golbus, J.R., Puckelwartz, M.J., Fahrenbach, J.P., et al. Population-based variation in cardiomyopathy genes. Circ Cardiovasc Genet 5 (2012), 391–399.
18. 18 Geisterfer-Lowrance, A.A.T., Kass, S., Tanigawa, G., et al. A molecular basis for familial hypertrophic cardiomyopathy: a β cardiac myosin heavy chain gene missense mutation. Cell 62 (1990), 999–1006.
19. 19 Tanigawa, G., Jarcho, J.A., Kass, S., et al. A molecular basis for familial hypertrophic cardiomyopathy: an α/β cardiac myosin heavy chain hybrid gene. Cell 62 (1990), 991–998.
20. 20 Thierfelder, L., Watkins, H., MacRae, C., et al. α-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77 (1994), 701–712.
21. 21 Watkins, H., McKenna, W.J., Thierfelder, L., et al. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 332 (1995), 1058–1064.
22. 22 Bonne, G., Carrier, L., Bercovici, J., et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 11 (1995), 438–440.
23. 23 Watkins, H., Conner, D., Thierfelder, L., et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 11 (1995), 434–437.
24. 24 Poetter, K., Jiang, H., Hassanzadeh, S., et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 13 (1996), 63–69.
25. 25 Kimura, A., Harada, H., Park, J.E., et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 16 (1997), 379–382.
26. 26 Mogensen, J., Klausen, I.C., Pedersen, A.K., et al. α-Cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 103 (1999), R39–R43.
27. 27 Olson, T.M., Doan, T.P., Kishimoto, N.Y., et al. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol 32 (2000), 1687–1694.
28. 28 Richard, P., Charron, P., Carrier, L., et al. Hypertrophic cardiomyopathy. Circulation 107 (2003), 2227–2232.
29. 29 Andersen, P.S., Havndrup, O., Hougs, L., et al. Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives. Hum Mutat 30 (2009), 363–370.
30. 30 Millat, G., Bouvagnet, P., Chevalier, P., et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet 53 (2010), 261–267.
31. 31 Curila, K., Benesova, L., Penicka, M., et al. Spectrum and clinical manifestations of mutations in genes responsible for hypertrophic cardiomyopathy. Acta Cardiol 67 (2012), 23–29.
32. 32 Brito, D., Miltenberger-Miltenyi, G., Vale Pereira, S., et al. Sarcomeric hypertrophic cardiomyopathy: genetic profile in a Portuguese population. Rev Port Cardiol 31 (2012), 577–587.
33. 33 Liu, W., Liu, W., Hu, D., et al. Mutation spectrum in a large cohort of unrelated Chinese patients with hypertrophic cardiomyopathy. Am J Cardiol 112 (2013), 585–589.
34. 34 Van Driest, S.L., Ommen, S.R., Tajik, A.J., et al. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin Proc 80 (2005), 739–744.
35. 35 Alfares, A.A., Kelly, M.A., McDermott, G., et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. [published correction appears in Genet Med 2015;17:319] Genet Med 17 (2015), 880–888.
36. 36 Solomon, S.D., Wolff, S., Watkins, H., et al. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol 22 (1993), 498–505.
37. 37 Binder, J., Ommen, S.R., Gersh, B.J., et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc 81 (2006), 459–467.
38. 38 Osio, A., Tan, L., Chen, S.N., et al. Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res 100 (2007), 766–768.
39. 39 Chiu, C., Bagnall, R.D., Ingles, J., et al. Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. J Am Coll Cardiol 55 (2010), 1127–1135.
40. 40 Satoh, M., Takahashi, M., Sakamoto, T., et al. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem Biophys Res Commun 262 (1999), 411–417.
41. 41 Bos, J.M., Poley, R.N., Ny, M., et al. Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Mol Genet Metabl 88 (2006), 78–85.
42. 42 Herman, D.S., Lam, L., Taylor, M.R.G., et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 366 (2012), 619–628.
43. 43 Knöll, R., Hoshijima, M., Hoffman, H.M., et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 111 (2002), 943–955.
44. 44 Geier, C., Gehmlich, K., Ehler, E., et al. Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy. Hum Mol Genet 17 (2008), 2753–2765.
45. 45 Geier, C., Perrot, A., Ozcelik, C., et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation 107 (2003), 1390–1395.
46. 46 Spudich, J.A., Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. Biophys J 106 (2014), 1236–1249.
47. 47 Green, E.M., Wakimoto, H., Anderson, R.L., et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351 (2016), 617–621.
48. 48 Harris, S.P., Lyons, R.G., Bezold, K.L., In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res 108 (2011), 751–764.
49. 49 Marston, S., Copeland, O.N., Jacques, A., et al. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res 105 (2009), 219–222.
50. 50 van Dijk, S.J., Dooijes, D., dos Remedios, C., et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 119 (2009), 1473–1483.
51. 51 Barefield, D., Kumar, M., Gorham, J., et al. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice. J Mol Cell Cardiol 79 (2015), 234–243.
52. 52 Tyska, M.J., Hayes, E., Giewat, M., et al. Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ Res 86 (2000), 737–744.
53. 53 Crilley, J.G., Boehm, E.A., Blair, E., et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 41 (2003), 1776–1782.
54. 54 Sommese, R.F., Sung, J., Nag, S., et al. Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function. Proc Natl Acad Sci U S A 110 (2013), 12607–12612.
55. 55 Bloemink, M., Deacon, J., Langer, S., et al. The hypertrophic cardiomyopathy myosin mutation R453C alters ATP binding and hydrolysis of human cardiac β-myosin. J Biol Chem 289 (2014), 5158–5167.
56. 56 Witjas-Paalberends, E.R., Güçlü, A., Germans, T., et al. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovasc Res 103 (2014), 248–257.
57. 57 Anan, R., Greve, G., Thierfelder, L., et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 93 (1994), 280–285.
58. 58 Ko, Y.L., Chen, J.J., Tang, T.K., et al. Malignant familial hypertrophic cardiomyopathy in a family with a 453Arg—>Cys mutation in the beta-myosin heavy chain gene: coexistence of sudden death and end-stage heart failure. Hum Genet 97 (1996), 585–590.
59. 59 Tesson, F., Richard, P., Charron, P., et al. Genotype-phenotype analysis in four families with mutations in β-myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy. Hum Mutat 12 (1998), 385–392.
60. 60 Niimura, H., Bachinski, L.L., Sangwatanaroj, S., et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 338 (1998), 1248–1257.
61. 61 Page, S.P., Kounas, S., Syrris, P., et al. Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome. Circ Cardiovasc Genet 5 (2012), 156–166.
62. 62 Seidman, C.E., Seidman, J.G., Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ Res 108 (2011), 743–750.
63. 63 Dhandapany, P.S., Sadayappan, S., Xue, Y., et al. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. Nat Genet 41 (2009), 187–191.
64. 64 Adalsteinsdottir, B., Teekakirikul, P., Maron, B.J., et al. Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation. Circulation 130 (2014), 1158–1167.
65. 65 Maron, B.J., Roberts, W.C., Arad, M., et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 301 (2009), 1253–1259.
66. 66 Sachdev, B., Takenaka, T., Teraguchi, H., et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105 (2002), 1407–1411.
67. 67 Chimenti, C., Pieroni, M., Morgante, E., et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110 (2004), 1047–1053.
68. 68 Monserrat, L., Gimeno-Blanes, J.R., Marín, F., et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 50 (2007), 2399–2403.
69. 69 Eng, C.M., Guffon, N., Wilcox, W.R., et al., International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345 (2001), 9–16.
70. 70 Banikazemi, M., Bultas, J., Waldek, S., et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146 (2007), 77–86.
71. 71 Kampmann, C., Perrin, A., Beck, M., Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment. Orphanet J Rare Dis, 10, 2015, 125.
72. 72 Kubo, T., Gimeno, J.R., Bahl, A., et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 49 (2007), 2419–2426.
73. 73 Kaski, J.P., Syrris, P., Burch, M., et al. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart 94 (2008), 1478–1484.
74. 74 Menon, S.C., Michels, V.V., Pellikka, P.A., et al. Cardiac troponin T mutation in familial cardiomyopathy with variable remodeling and restrictive physiology. Clin Genet 74 (2008), 445–454.
75. 75 Wu, W., Lu, C.X., Wang, Y.N., et al. Novel phenotype-genotype correlations of restrictive cardiomyopathy with myosin-binding protein C (MYBPC3) gene mutations tested by next-generation sequencing. J Am Heart Assoc, 4, 2015, e001879.
76. 76 Zhang, J., Kumar, A., Stalker, H.J., et al. Clinical and molecular studies of a large family with desmin-associated restrictive cardiomyopathy. Clin Genet 59 (2001), 248–256.
77. 77 Purevjav, E., Arimura, T., Augustin, S., et al. Molecular basis for clinical heterogeneity in inherited cardiomyopathies due to myopalladin mutations. Hum Mol Genet 21 (2012), 2039–2053.
78. 78 Duboscq-Bidot, L., Xu, P., Charron, P., et al. Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy. Cardiovasc Res 77 (2008), 118–125.
79. 79 Bagnall, R.D., Yeates, L., Semsarian, C., Analysis of the Z-disc genes PDLIM3 and MYPN in patients with hypertrophic cardiomyopathy. Int J Cardiol 145 (2010), 601–602.
80. 80 Mogensen, J., Kubo, T., Duque, M., et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. [Published correction appears in J Clin Invest 2003;111:925] J Clin Invest 111 (2003), 209–216.
81. 81 Du, J., Liu, J., Feng, H.Z., et al. Impaired relaxation is the main manifestation in transgenic mice expressing a restrictive cardiomyopathy mutation, R193H, in cardiac TnI. Am J Physiol Heart Circ Physiol 294 (2008), H2604–H2613.
82. 82 Huby, A.C., Mendsaikhan, U., Takagi, K., et al. Disturbance in Z-disk mechanosensitive proteins induced by a persistent mutant myopalladin causes familial restrictive cardiomyopathy. J Am Coll Cardiol 64 (2014), 2765–2776.
83. 83 Kasper, E.K., Agema, W.R., Hutchins, G.M., et al. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 23 (1994), 586–590.
84. 84 Codd, M.B., Sugrue, D.D., Gersh, B.J., et al. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984. Circulation 80 (1989), 564–572.
85. 85 Hershberger, R.E., Hedges, D.J., Morales, A., Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol 10 (2013), 531–547.
86. 86 Gerull, B., Gramlich, M., Atherton, J., et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 30 (2002), 201–204.
87. 87 Norton, N., Li, D., Rampersaud, E., et al., National Heart, Lung, and Blood Institute GO Exome Sequencing Project and the Exome Sequencing Project Family Studies Project Team. Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. Circ Cardiovasc Genet 6 (2013), 144–153.
88. 88 Roberts, A.M., Ware, J.S., Herman, D.S., et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med, 7, 2015, 270ra6.
89. 89 Hinson, J.T., Chopra, A., Nafissi, N., et al. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science 349 (2015), 982–986.
90. 90 Locus Reference Genomic. 2011. Available at: http://www.lrg-sequence.org. Accessed October 17, 2016.
91. 91 Maatz, H., Jens, M., Liss, M., et al. RNA-binding protein RBM20 represses splicing to orchestrate cardiac pre-mRNA processing. J Clin Invest 124 (2014), 3419–3430.
92. 92 Guo, W., Schafer, S., Greaser, M.L., et al. RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med 18 (2012), 766–773.
93. 93 Brauch, K.M., Karst, M.L., Herron, K.J., et al. Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J Am Coll Cardiol 54 (2009), 930–941.
94. 94 Li, D., Morales, A., Gonzalez-Quintana, J., et al. Identification of novel mutations in RBM20 in patients with dilated cardiomyopathy. Clin Transl Sci 3 (2010), 90–97.
95. 95 Millat, G., Bouvagnet, P., Chevalier, P., et al. Clinical and mutational spectrum in a cohort of 105 unrelated patients with dilated cardiomyopathy. Eur J Med Genet 54 (2011), e570–e575.
96. 96 Wells, Q.S., Becker, J.R., Su, Y.R., et al. Whole exome sequencing identifies a causal RBM20 mutation in a large pedigree with familial dilated cardiomyopathy. Circ Cardiovasc Genet 6 (2013), 317–326.
97. 97 Schmitt, J.P., Kamisago, M., Asahi, M., et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299 (2003), 1410–1413.
98. 98 Haghighi, K., Kolokathis, F., Pater, L., et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 111 (2003), 869–876.
99. 99 Haghighi, K., Kolokathis, F., Gramolini, A.O., et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci U S A 103 (2006), 1388–1393.
100. 100 Truszkowska, G.T., Bilińska, Z.T., Kosińska, J., et al. A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations. BMC Med Genet, 16, 2015, 21.
101. 101 Fish, M., Shaboodien, G., Kraus, S., et al. Mutation analysis of the phospholamban gene in 315 South Africans with dilated, hypertrophic, peripartum and arrhythmogenic right ventricular cardiomyopathies. Sci Rep, 6, 2016, 22235.
102. 2+-ATPase regulation and phosphorylation by protein kinase A. Proc Natl Acad Sci U S A 108 (2011), 2735–2740.
103. 103 Abrol, N., de Tombe, P.P., Robia, S.L., Acute inotropic and lusitropic effects of cardiomyopathic R9C mutation of phospholamban. J Biol Chem 290 (2015), 7130–7140.
104. 104 DeWitt, M.M., MacLeod, H.M., Soliven, B., et al. Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J Am Coll Cardiol 48 (2006), 1396–1398.
105. 105 van der Zwaag, P.A., van Rijsingen, I.A., Asimaki, A., et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail 14 (2012), 1199–1207.
106. 106 Olson, T.M., Keating, M.T., Mapping a cardiomyopathy locus to chromosome 3p22-p25. J Clin Invest 97 (1996), 528–532.
107. 107 McNair, W.P., Ku, L., Taylor, M.R.G., et al., Familial Cardiomyopathy Registry Research Group. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation 110 (2004), 2163–2167.
108. 108 Olson, T.M., Michels, V.V., Ballew, J.D., et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 293 (2005), 447–454.
109. 109 McNair, W.P., Sinagra, G., Taylor, M.R.G., et al., Familial Cardiomyopathy Registry Research Group. SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism. J Am Coll Cardiol 57 (2011), 2160–2168.
110. 110 Chen, Q., Kirsch, G.E., Zhang, D., et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392 (1998), 293–296.
111. 111 Watanabe, H., Nogami, A., Ohkubo, K., et al. Electrocardiographic characteristics and SCN5A mutations in idiopathic ventricular fibrillation associated with early repolarization. Circ Arrhythm Electrophysiol 4 (2011), 874–881.
112. 112 Ellinor, P.T., Nam, E.G., Shea, M.A., et al. Cardiac sodium channel mutation in atrial fibrillation. Heart Rhythm 5 (2008), 99–105.
113. 113 McNally, E.M., Golbus, J.R., Puckelwartz, M.J., Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest 123 (2013), 19–26.
114. 114 Fatkin, D., MacRae, C., Sasaki, T., et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 341 (1999), 1715–1724.
115. 115 Taylor, M.R.G., Fain, P.R., Sinagra, G., et al., Familial Dilated Cardiomyopathy Registry Research Group. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 41 (2003), 771–780.
116. 116 Nikolova, V., Leimena, C., McMahon, A.C., et al. Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. J Clin Invest 113 (2004), 357–369.
117. 117 Pasotti, M., Klersy, C., Pilotto, A., et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 52 (2008), 1250–1260.
118. 118 van Rijsingen, I.A.W., Arbustini, E., Elliott, P.M., et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol 59 (2012), 493–500.
119. 119 Meune, C., Van Berlo, J.H., Anselme, F., et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med 354 (2006), 209–210.
120. 120 Anselme, F., Moubarak, G., Savouré, A., et al. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm 10 (2013), 1492–1498.
121. 121 Arbustini, E., Weidemann, F., Hall, J.L., Left ventricular noncompaction: a distinct cardiomyopathy or a trait shared by different cardiac diseases?. J Am Coll Cardiol 64 (2014), 1840–1850.
122. 122 Hussein, A., Karimianpour, A., Collier, P., et al. Isolated noncompaction of the left ventricle in adults. J Am Coll Cardiol 66 (2015), 578–585.
123. 123 Marcus, F.I., Edson, S., Towbin, J.A., Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. J Am Coll Cardiol 61 (2013), 1945–1948.
124. 124 Meyers, D.E., Basha, H.I., Koenig, M.K., Mitochondrial cardiomyopathy: pathophysiology, diagnosis, and management. Tex Heart Inst J 40 (2013), 385–394.
125. 125 Mogensen, J., Arbustini, E., Restrictive cardiomyopathy. Curr Opin Cardiol 24 (2009), 214–220.
126. 126 GeneTests. 2016. Available at: https://www.genetests.org. Accessed October 17, 2016.
127. 127 GTR: Genetic Testing Registry. National Institutes of Health. Available at: https://www.ncbi.nlm.nih.gov/gtr/. Accessed August 1, 2016.
128. 128 Hershberger, R.E., Cowan, J., Morales, A., et al. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2 (2009), 253–261.
129. 129 Levine, B.D., Baggish, A.L., Kovacs, R.J., et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 1: Classification of Sports: Dynamic, Static, and Impact: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol 66 (2015), 2350–2355.
130. 130 Maron, B.J., Levine, B.D., Washington, R.L., et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol 66 (2015), 2356–2361.
131. 131 Maron, B.J., Udelson, J.E., Bonow, R.O., et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol 66 (2015), 2362–2371.
132. 132 Karakikes, I., Termglinchan, V., Wu, J.C., Human-induced pluripotent stem cell models of inherited cardiomyopathies. Curr Opin Cardiol 29 (2014), 214–219.
133. 133 Dorn, G.W. 2nd, McNally, E.M., Two strikes and you're out: gene-gene mutation interactions in HCM. Circ Res 115 (2014), 208–210.
134. 134 Ho, C.Y., López, B., Coelho-Filho, O.R., et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 363 (2010), 552–563.
135. 135 Lakdawala, N.K., Thune, J.J., Colan, S.D., et al. Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. Circ Cardiovasc Genet 5 (2012), 503–510.
136. 136 Valente, A.M., Lakdawala, N.K., Powell, A.J., et al. Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy. Circ Cardiovasc Genet 6 (2013), 230–237.
137. 137 Lim, D.S., Lutucuta, S., Bachireddy, P., et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103 (2001), 789–791.
138. 138 Teekakirikul, P., Eminaga, S., Toka, O., et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest 120 (2010), 3520–3529.
139. 139 Shimada, Y.J., Passeri, J.J., Baggish, A.L., et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol HF 1 (2013), 480–487.
140. 140 Ho, C.Y., Lakdawala, N.K., Cirino, A.L., et al. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. J Am Coll Cardiol HF 3 (2015), 180–188.
141. 141 Axelsson, A., Iversen, K., Vejlstrup, N., et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 3 (2015), 123–131.
142. 142 Jiang, J., Wakimoto, H., Seidman, J.G., et al. Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science 342 (2013), 111–114.
143. 143 Hershberger, R.E., Lindenfeld, J., Mestroni, L., et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America Practice Guideline. J Card Fail 15 (2009), 83–97.
144. 144 Ackerman, M.J., Priori, S.G., Willems, S., et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Europace 13 (2011), 1077–1109.